Holen Sie sich die Stockscreener-App
2.83
0.00%
0.00
Handel nachbörslich:
2.80
-0.03
-1.06%
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Form 4 Biomarin Pharmaceutical Inc For: 1 October By Investing.com - Investing.com UK
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Form 4 ANI Pharmaceuticals Inc For: 1 October By Investing.com - Investing.com Nigeria
Form 4 Oric Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals stock gets a smaller Phase 3 trial - AD HOC NEWS
Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com - Investing.com Canada
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com Nigeria
Form 4 Oric Pharmaceuticals Inc For: 25 September - Investing.com India
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Business Wire
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround - Yahoo Finance
X4 Pharmaceuticals stock falls 9.33 percent to USD 3.11 - AD HOC NEWS
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com - Investing.com Canada
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September - Investing.com India
Layoff Tracker: Novo workforce down 13,000 - BioSpace
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com Nigeria
Over 5.5M shares in X4 Pharmaceuticals (XFOR) now held by one investor group - Stock Titan
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to S&P Global BMI Index - marketscreener.com
X4 Pharmaceuticals Inc (48Q0) Q3 2022 Earnings ReportResults, Call & Slides - TipRanks
X4 Pharmaceuticals Inc (48Q0) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
X4 Pharmaceuticals stock holds firm before November 5 earnings - AD HOC NEWS
X4 Pharmaceuticals, Inc. (XFOR) Latest Stock News & Headlines - Yahoo Finance
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook By Investing.com - Investing.com India
XFOR: Phase III enrollment for mavorixafor nears completion, with data and launch expected by early 2029 - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) Secures FDA Approval for Reduced Sample Size in 4WARD Trial, Data Expected in Early 2028 - Kalkine Media
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - markets.businessinsider.com
Wells Fargo’s healthcare conference will include an X4 Pharmaceuticals talk Sept. 10 - Stock Titan
X4 Pharmaceuticals Advances Mavorixafor Strategy in Chronic Neutropenia - TipRanks
X4 posts updated corporate presentation; full 4WARD enrollment expected Q4 2026, topline data H1 2028 - TradingView
X4 Pharmaceuticals (XFOR) outlines path to possible 2029 FDA approval - Stock Titan
X4 Pharmaceuticals: FDA OKs Reduced Sample Size for 4WARD Phase 3, Enrollment to Finish by Year-End 2026 - TradingView
FDA backs smaller late-stage test of X4 (NASDAQ: XFOR) neutropenia drug, with pivotal data not due until 2028 - Stock Titan
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting - Yahoo Finance
X4 Pharmaceuticals Stock Price Forecast. Should You Buy XFOR? - StockInvest.us
ETFs Investing in X4 Pharmaceuticals, Inc. Stocks - TradingView
X4 Pharmaceuticals Inc. (XFOR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
X4 Pharmaceuticals Inc. (XFOR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
X4 Pharmaceuticals Inc. (XFOR) Peer Comparison – Compare with Others - Value Research
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView
X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha
X4 (XFOR) Share-Price Review: Closes 2.09% Lower at $4.21 in the Current Update; Price-Level Context: the Near-Term Reference Band Stretches From $4.00 to $4.42 in Latest TradingChandelier Stop - vinanet.vn
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Study Explores Industry Growth Toward $2.75 Billion - openPR.com
Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan
X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media
John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat
X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com
X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com India
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):